Financhill
Sell
43

CLRB Quote, Financials, Valuation and Earnings

Last price:
$0.31
Seasonality move :
2.33%
Day range:
$0.29 - $0.33
52-week range:
$0.22 - $4.45
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
657.46x
P/B ratio:
8.23x
Volume:
2.6M
Avg. volume:
3.4M
1-year change:
-88.12%
Market cap:
$12.7M
Revenue:
--
EPS (TTM):
-$1.90

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
CLRB
Cellectar Biosciences
-- -$0.37 -- -33.33% $5.67
APLT
Applied Therapeutics
-- -$0.16 -76.55% -43.43% $6.80
IONS
Ionis Pharmaceuticals
$129.9M -$0.98 -56.49% -1312.97% $61.36
LGND
Ligand Pharmaceuticals
$40.6M $1.35 38.83% 14.72% --
RVNC
Revance Therapeutics
$68.2M -$0.40 4.53% -57.94% $7.64
ZYME
Zymeworks
$17.9M -$0.41 286.36% -0.36% $19.86
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
CLRB
Cellectar Biosciences
$0.31 $5.67 $12.7M -- $0.00 0% 657.46x
APLT
Applied Therapeutics
$0.85 $6.80 $99.3M -- $0.00 0% --
IONS
Ionis Pharmaceuticals
$35.91 $61.36 $5.7B -- $0.00 0% 6.53x
LGND
Ligand Pharmaceuticals
$109.19 -- $2.1B 43.50x $0.00 0% 12.94x
RVNC
Revance Therapeutics
$3.06 $7.64 $321M -- $0.00 0% 1.15x
ZYME
Zymeworks
$14.50 $19.86 $998.7M -- $0.00 0% 17.46x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
CLRB
Cellectar Biosciences
-- 0.805 -- --
APLT
Applied Therapeutics
-- 4.461 -- 1.00x
IONS
Ionis Pharmaceuticals
65.87% -0.031 20.22% 8.21x
LGND
Ligand Pharmaceuticals
-- 1.574 -- 10.57x
RVNC
Revance Therapeutics
160.8% 0.786 79.2% 2.90x
ZYME
Zymeworks
-- 1.327 -- 3.82x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
CLRB
Cellectar Biosciences
-- -$13.3M -- -- -- -$9.2M
APLT
Applied Therapeutics
-- -$29.7M -790.52% -797.82% -24379.51% -$23.3M
IONS
Ionis Pharmaceuticals
$132.7M -$148.6M -21.57% -93.21% -91.82% -$111.3M
LGND
Ligand Pharmaceuticals
$49.4M $11M 5.97% 5.97% -10.8% $22.3M
RVNC
Revance Therapeutics
$42.2M -$32.3M -61.49% -- -49.91% -$41.2M
ZYME
Zymeworks
-- -$34.3M -27.06% -27.06% -214.08% -$6.9M

Cellectar Biosciences vs. Competitors

  • Which has Higher Returns CLRB or APLT?

    Applied Therapeutics has a net margin of -- compared to Cellectar Biosciences's net margin of -56222.13%. Cellectar Biosciences's return on equity of -- beat Applied Therapeutics's return on equity of -797.82%.

    Company Gross Margin Earnings Per Share Invested Capital
    CLRB
    Cellectar Biosciences
    -- -$0.40 --
    APLT
    Applied Therapeutics
    -- -$0.48 $5.9M
  • What do Analysts Say About CLRB or APLT?

    Cellectar Biosciences has a consensus price target of $5.67, signalling upside risk potential of 1735.06%. On the other hand Applied Therapeutics has an analysts' consensus of $6.80 which suggests that it could grow by 593.39%. Given that Cellectar Biosciences has higher upside potential than Applied Therapeutics, analysts believe Cellectar Biosciences is more attractive than Applied Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    CLRB
    Cellectar Biosciences
    1 1 0
    APLT
    Applied Therapeutics
    3 3 0
  • Is CLRB or APLT More Risky?

    Cellectar Biosciences has a beta of 0.891, which suggesting that the stock is 10.942% less volatile than S&P 500. In comparison Applied Therapeutics has a beta of 1.765, suggesting its more volatile than the S&P 500 by 76.451%.

  • Which is a Better Dividend Stock CLRB or APLT?

    Cellectar Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Applied Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cellectar Biosciences pays -- of its earnings as a dividend. Applied Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CLRB or APLT?

    Cellectar Biosciences quarterly revenues are --, which are smaller than Applied Therapeutics quarterly revenues of $122K. Cellectar Biosciences's net income of -$14.7M is higher than Applied Therapeutics's net income of -$68.6M. Notably, Cellectar Biosciences's price-to-earnings ratio is -- while Applied Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cellectar Biosciences is 657.46x versus -- for Applied Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CLRB
    Cellectar Biosciences
    657.46x -- -- -$14.7M
    APLT
    Applied Therapeutics
    -- -- $122K -$68.6M
  • Which has Higher Returns CLRB or IONS?

    Ionis Pharmaceuticals has a net margin of -- compared to Cellectar Biosciences's net margin of -104.98%. Cellectar Biosciences's return on equity of -- beat Ionis Pharmaceuticals's return on equity of -93.21%.

    Company Gross Margin Earnings Per Share Invested Capital
    CLRB
    Cellectar Biosciences
    -- -$0.40 --
    IONS
    Ionis Pharmaceuticals
    99.2% -$0.95 $1.9B
  • What do Analysts Say About CLRB or IONS?

    Cellectar Biosciences has a consensus price target of $5.67, signalling upside risk potential of 1735.06%. On the other hand Ionis Pharmaceuticals has an analysts' consensus of $61.36 which suggests that it could grow by 70.87%. Given that Cellectar Biosciences has higher upside potential than Ionis Pharmaceuticals, analysts believe Cellectar Biosciences is more attractive than Ionis Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    CLRB
    Cellectar Biosciences
    1 1 0
    IONS
    Ionis Pharmaceuticals
    13 7 0
  • Is CLRB or IONS More Risky?

    Cellectar Biosciences has a beta of 0.891, which suggesting that the stock is 10.942% less volatile than S&P 500. In comparison Ionis Pharmaceuticals has a beta of 0.349, suggesting its less volatile than the S&P 500 by 65.148%.

  • Which is a Better Dividend Stock CLRB or IONS?

    Cellectar Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cellectar Biosciences pays -- of its earnings as a dividend. Ionis Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CLRB or IONS?

    Cellectar Biosciences quarterly revenues are --, which are smaller than Ionis Pharmaceuticals quarterly revenues of $133.8M. Cellectar Biosciences's net income of -$14.7M is higher than Ionis Pharmaceuticals's net income of -$140.5M. Notably, Cellectar Biosciences's price-to-earnings ratio is -- while Ionis Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cellectar Biosciences is 657.46x versus 6.53x for Ionis Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CLRB
    Cellectar Biosciences
    657.46x -- -- -$14.7M
    IONS
    Ionis Pharmaceuticals
    6.53x -- $133.8M -$140.5M
  • Which has Higher Returns CLRB or LGND?

    Ligand Pharmaceuticals has a net margin of -- compared to Cellectar Biosciences's net margin of -13.84%. Cellectar Biosciences's return on equity of -- beat Ligand Pharmaceuticals's return on equity of 5.97%.

    Company Gross Margin Earnings Per Share Invested Capital
    CLRB
    Cellectar Biosciences
    -- -$0.40 --
    LGND
    Ligand Pharmaceuticals
    95.27% -$0.39 $841.2M
  • What do Analysts Say About CLRB or LGND?

    Cellectar Biosciences has a consensus price target of $5.67, signalling upside risk potential of 1735.06%. On the other hand Ligand Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 31.88%. Given that Cellectar Biosciences has higher upside potential than Ligand Pharmaceuticals, analysts believe Cellectar Biosciences is more attractive than Ligand Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    CLRB
    Cellectar Biosciences
    1 1 0
    LGND
    Ligand Pharmaceuticals
    3 0 0
  • Is CLRB or LGND More Risky?

    Cellectar Biosciences has a beta of 0.891, which suggesting that the stock is 10.942% less volatile than S&P 500. In comparison Ligand Pharmaceuticals has a beta of 1.038, suggesting its more volatile than the S&P 500 by 3.81%.

  • Which is a Better Dividend Stock CLRB or LGND?

    Cellectar Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ligand Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cellectar Biosciences pays -- of its earnings as a dividend. Ligand Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CLRB or LGND?

    Cellectar Biosciences quarterly revenues are --, which are smaller than Ligand Pharmaceuticals quarterly revenues of $51.8M. Cellectar Biosciences's net income of -$14.7M is lower than Ligand Pharmaceuticals's net income of -$7.2M. Notably, Cellectar Biosciences's price-to-earnings ratio is -- while Ligand Pharmaceuticals's PE ratio is 43.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cellectar Biosciences is 657.46x versus 12.94x for Ligand Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CLRB
    Cellectar Biosciences
    657.46x -- -- -$14.7M
    LGND
    Ligand Pharmaceuticals
    12.94x 43.50x $51.8M -$7.2M
  • Which has Higher Returns CLRB or RVNC?

    Revance Therapeutics has a net margin of -- compared to Cellectar Biosciences's net margin of -63.65%. Cellectar Biosciences's return on equity of -- beat Revance Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    CLRB
    Cellectar Biosciences
    -- -$0.40 --
    RVNC
    Revance Therapeutics
    70.55% -$0.37 $268.2M
  • What do Analysts Say About CLRB or RVNC?

    Cellectar Biosciences has a consensus price target of $5.67, signalling upside risk potential of 1735.06%. On the other hand Revance Therapeutics has an analysts' consensus of $7.64 which suggests that it could grow by 149.58%. Given that Cellectar Biosciences has higher upside potential than Revance Therapeutics, analysts believe Cellectar Biosciences is more attractive than Revance Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    CLRB
    Cellectar Biosciences
    1 1 0
    RVNC
    Revance Therapeutics
    1 7 0
  • Is CLRB or RVNC More Risky?

    Cellectar Biosciences has a beta of 0.891, which suggesting that the stock is 10.942% less volatile than S&P 500. In comparison Revance Therapeutics has a beta of 0.815, suggesting its less volatile than the S&P 500 by 18.478%.

  • Which is a Better Dividend Stock CLRB or RVNC?

    Cellectar Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Revance Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cellectar Biosciences pays -- of its earnings as a dividend. Revance Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CLRB or RVNC?

    Cellectar Biosciences quarterly revenues are --, which are smaller than Revance Therapeutics quarterly revenues of $59.9M. Cellectar Biosciences's net income of -$14.7M is higher than Revance Therapeutics's net income of -$38.1M. Notably, Cellectar Biosciences's price-to-earnings ratio is -- while Revance Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cellectar Biosciences is 657.46x versus 1.15x for Revance Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CLRB
    Cellectar Biosciences
    657.46x -- -- -$14.7M
    RVNC
    Revance Therapeutics
    1.15x -- $59.9M -$38.1M
  • Which has Higher Returns CLRB or ZYME?

    Zymeworks has a net margin of -- compared to Cellectar Biosciences's net margin of -186.56%. Cellectar Biosciences's return on equity of -- beat Zymeworks's return on equity of -27.06%.

    Company Gross Margin Earnings Per Share Invested Capital
    CLRB
    Cellectar Biosciences
    -- -$0.40 --
    ZYME
    Zymeworks
    -- -$0.39 $367M
  • What do Analysts Say About CLRB or ZYME?

    Cellectar Biosciences has a consensus price target of $5.67, signalling upside risk potential of 1735.06%. On the other hand Zymeworks has an analysts' consensus of $19.86 which suggests that it could grow by 36.94%. Given that Cellectar Biosciences has higher upside potential than Zymeworks, analysts believe Cellectar Biosciences is more attractive than Zymeworks.

    Company Buy Ratings Hold Ratings Sell Ratings
    CLRB
    Cellectar Biosciences
    1 1 0
    ZYME
    Zymeworks
    5 2 0
  • Is CLRB or ZYME More Risky?

    Cellectar Biosciences has a beta of 0.891, which suggesting that the stock is 10.942% less volatile than S&P 500. In comparison Zymeworks has a beta of 1.121, suggesting its more volatile than the S&P 500 by 12.109%.

  • Which is a Better Dividend Stock CLRB or ZYME?

    Cellectar Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zymeworks offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cellectar Biosciences pays -- of its earnings as a dividend. Zymeworks pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CLRB or ZYME?

    Cellectar Biosciences quarterly revenues are --, which are smaller than Zymeworks quarterly revenues of $16M. Cellectar Biosciences's net income of -$14.7M is higher than Zymeworks's net income of -$29.9M. Notably, Cellectar Biosciences's price-to-earnings ratio is -- while Zymeworks's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cellectar Biosciences is 657.46x versus 17.46x for Zymeworks. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CLRB
    Cellectar Biosciences
    657.46x -- -- -$14.7M
    ZYME
    Zymeworks
    17.46x -- $16M -$29.9M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Is Coinbase Stock Going Down?
Why Is Coinbase Stock Going Down?

Every way you look at it, Coinbase has had a…

Is Uber Stock a Buy on the Dip?
Is Uber Stock a Buy on the Dip?

Shares of Uber Technologies (NYSE:UBER) have been fading fast in…

Is AMD Stock an All-Time Buy?
Is AMD Stock an All-Time Buy?

Advanced Micro Devices (NASDAQ:AMD) is a high-growth AI stock that…

Stock Ideas

Buy
64
Is AAPL Stock a Buy?

Market Cap: $3.9T
P/E Ratio: 42x

Buy
52
Is NVDA Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 115x

Buy
54
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 36x

Alerts

Sell
50
LMND alert for Dec 28

Lemonade [LMND] is down 10.69% over the past day.

Sell
50
TSLL alert for Dec 28

Direxion Daily TSLA Bull 2X Shares [TSLL] is down 9.92% over the past day.

Buy
63
SMLR alert for Dec 28

Semler Scientific [SMLR] is down 9.65% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock